Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Evaluation of the clinical performance of high-risk human papillomavirus testing for primary screening: a retrospective review of the Southern California Permanente Medical Group experience.

Lonky NM, Mahdavi A, Wolde-Tsadik G, Bajamundi K, Felix JC.

J Low Genit Tract Dis. 2010 Jul;14(3):200-5. doi: 10.1097/LGT.0b013e3181cc3f3e.

PMID:
20592555
2.

[Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].

Qian DY, Cen JM, Wang D, Zeng RH, Lin AH, Shu YH, Hong DH, Huang ZH.

Zhonghua Fu Chan Ke Za Zhi. 2006 Jan;41(1):34-7. Chinese.

PMID:
16635326
3.

[Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].

Guo YL, You K, Geng L, Zhang XW, Shen XY, Yao YJ, Fan XH.

Beijing Da Xue Xue Bao. 2006 Oct 18;38(5):480-2. Chinese.

4.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

5.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
6.

Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.

Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, Schincaglia P, Zorzi M, Confortini M, Cuzick J; New Technologies for Cervical Cancer Working Group.

J Natl Cancer Inst. 2006 Jun 7;98(11):765-74.

7.

[Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].

Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.

Zhonghua Yi Xue Za Zhi. 2006 Feb 7;86(5):307-11. Chinese.

PMID:
16677522
8.

HPV testing in primary screening of older women.

Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P.

Br J Cancer. 1999 Oct;81(3):554-8.

9.

[Study on the genotyping of human papillomavirus using a new DNA liquid chip in women of high-risk group of Shandong province].

Liu M, Wang CX, Deng XM, Wang LS, Zhang J, Li W, Zheng GX, Wang JF.

Zhonghua Liu Xing Bing Xue Za Zhi. 2007 May;28(5):487-90. Chinese.

PMID:
17877181
10.

Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.

Luyten A, Scherbring S, Reinecke-Lüthge A, Braun BE, Pietralla M, Theiler K, Petry KU.

J Clin Virol. 2009 Nov;46 Suppl 3:S5-10. doi: 10.1016/S1386-6532(09)70294-X.

PMID:
20129072
13.
14.

Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up.

Davey DD, Greenspan DL, Kurtycz DF, Husain M, Austin RM.

J Low Genit Tract Dis. 2010 Jul;14(3):206-14. doi: 10.1097/LGT.0b013e3181ca66a6. Review.

PMID:
20592556
15.

Contribution of human papillomavirus testing by hybrid capture in the triage of women with repeated abnormal pap smears before colposcopy referral.

Fait G, Kupferminc MJ, Daniel Y, Geva E, Ron IG, Lessing JB, Bar-Am A.

Gynecol Oncol. 2000 Nov;79(2):177-80.

PMID:
11063640
16.

Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, Rylander E, Dillner J.

J Natl Cancer Inst. 2009 Jan 21;101(2):88-99. doi: 10.1093/jnci/djn444. Epub 2009 Jan 13.

17.

Does typing of human papillomavirus assist in the triage of women with repeated low-grade, cervical cytologic abnormalities?

Fait G, Daniel Y, Kupferminc MJ, Lessing JB, Niv J, Bar-Am A.

Gynecol Oncol. 1998 Sep;70(3):319-22.

PMID:
9790781
18.

Human papillomavirus triage for young women with atypical squamous cells of undetermined significance.

Wright JD, Rader JS, Davila R, Powell MA, Mutch DG, Gao F, Gibb RK.

Obstet Gynecol. 2006 Apr;107(4):822-9.

PMID:
16582118
19.

Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.

Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M, Poppe W.

BJOG. 2006 Nov;113(11):1303-7. Epub 2006 Sep 15.

20.

High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.

Denise Zielinski G, Snijders PJ, Rozendaal L, Voorhorst FJ, Runsink AP, de Schipper FA, Meijer CJ.

J Pathol. 2001 Oct;195(3):300-6.

PMID:
11673826
Items per page

Supplemental Content

Write to the Help Desk